Saturday 17 October 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.8%, EPS fell 35.9% and free cash flow fell 1.87%, each against the same quarter a year earlier.
16.35
0.96
−5.55%
Follow BBNX
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 5 |
Altman Z-Score |
— | — | 16.89 |
P/S ratio |
2.42 | 2.42 | 12.32 |
Altman Z″-Score (non-manufacturers) |
(4.13) | (4.25) | 6.94 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
(11.03) | (11.03) | (143.15) |
Beneish M-Score |
— | 1.27 | (1.86) |
P/B ratio |
0.00 | 0.00 | 4.29 |
Price to Tangible BV |
0.00 | 0.00 | 4.29 |
EV/Sales |
0.83 | 0.83 | 10.13 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.12) | (1.12) | (19.94) |
EV/FCF |
(1.04) | (1.04) | (3.05) |
Quick Ratio |
9.54 | 5.46 | 7.64 |
Current Ratio |
9.77 | 6.29 | 8.66 |
Net Debt/EBITDA |
2.87 | 2.41 | 3.19 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.50 | 0.42 |
Operating CF/Net income |
0.74 | 0.88 | 0.70 |
Capex/Depreciation |
(0.19) | (31.57) | (98.10) |
| 0.00% | 24.42% | (346.51%) | |
| 0.00% | (42.17%) | (30.60%) | |
ROIC |
0.00% | 0.00% | (65.51%) |
Return on Tangible Assets |
(46.18%) | (46.98%) | (29.81%) |
Average Days of Receivables |
135.35 | 67.23 | 62.32 |
Research and Development Expense of Revenue |
149.59% | 40.21% | 34.70% |
Selling, General and Administrative Expense of Revenue |
201.88% | 84.39% | 92.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
47.17% | 9.80% | 16.34% |
Graham Net Nets |
(1.66) | (1.66) | 0.18 |
Graham Number |
0.00 | 84.48 | 0.00 |
Earnings Yield |
(36.47%) | (36.47%) | (6.40%) |
Free Cash Flow Yield |
(32.77%) | (32.77%) | (26.96%) |
Revenue per Share |
2.26 | 10.23 | 2.47 |
Operating CF per Share |
(6.12) | (7.58) | (1.26) |
Capex per Share |
(0.07) | (11.32) | (6.96) |
Free Cash Flow per Share |
(6.19) | (18.91) | (8.22) |
Cash per Share |
18.24 | 16.27 | 5.41 |
Shareholders Equity per Share |
(38.29) | (38.55) | 7.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(38.29) | (38.55) | 7.10 |
Free Cash Flow |
(32.84) | (120.35) | (332.96) |
Working Capital |
93.02 | 111.78 | 236.98 |
Capital Expenditures |
(0.40) | (72.08) | (282.03) |
Net Current Asset Value |
(209.52) | (262.08) | 226.77 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 1.11 | 2.81 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.84 | 0.48 | 0.33 |
Cash ROIC |
30.88% | 84.88% | (65.69%) |
Accounts Receivable Turnover |
0.00 | 7.92 | 6.89 |
Accounts Payable Turnover |
0.00 | 14.55 | 11.39 |
Inventory Turnover |
0.00 | 4.01 | 2.55 |
Average Days of Payables |
74.84 | 35.61 | 40.80 |
Days of Inventory on Hand |
79.91 | 166.30 | 177.32 |
Average Receivables |
— | 8.22 | 14.56 |
Average Payables |
— | 2.01 | 3.93 |
Average Inventory |
— | 7.28 | 17.52 |
Average Assets |
— | 129.84 | 239.19 |
Average Common Equity |
— | (224.23) | 21.13 |
Columns are period end dates